CA-RUBICON-CARBON
9.7.2024 15:01:29 CEST | Business Wire | Press release
Rubicon Carbon, a carbon credit management firm, today announced a new partnership with Formula E Champion and ABT CUPRA driver Lucas di Grassi to purchase carbon credits using the company’s platform. Di Grassi is the first Formula E driver to offset his carbon footprint by personally investing in carbon credits.
Di Grassi built his own Rubicon Carbon Tonne (RCT), a diversified and actively managed portfolio of carbon credits that includes carbon removal, nature-based avoidance, and industrial avoidance projects. Through RCTs, buyers reduce risk and increase optionality and price certainty.
"We are excited to support Lucas and Formula E, who share our values in building a low-carbon future," said Tom Montag, CEO of Rubicon Carbon. "This partnership perfectly aligns with our mission to innovate and lead in the fight against climate change, and we look forward to helping Lucas on his path to decarbonizing the mobility and racing industries.”
To celebrate the partnership, di Grassi’s car and helmet proudly displayed Rubicon Carbon logos at last month’s Hankook Portland E-Prix in Portland, Oregon. The collaboration between Rubicon Carbon and di Grassi exemplifies the potential of sports partnerships to drive positive environmental change.
As an activist in mobility technology and the first Formula E driver to publicly sever ties with industries that do not prioritize sustainability, di Grassi has set a precedent for how to champion environmental responsibility as a professional athlete.
Speaking on the partnership, di Grassi noted, “I am proud to be the first driver to offset all the carbon I have emitted from traveling around the world since my first Formula E race in Beijing. Working with (Rubicon Carbon CEO) Tom Montag and his entire team is the perfect partnership for me, as Rubicon Carbon is the most qualified and credible carbon credit management firm in the world. In line with the values and objectives of Formula E, I drive an electric car and have adapted my lifestyle. But still, credible carbon avoidance and removal is the only way to do the sport we love and be responsible for our environment at the same time. I would be delighted if many other athletes, not only in Formula E, would consider the same path.”
This partnership follows Rubicon’s recent investments in carbon projects across the globe, including a large-scale ecosystem restoration project in Panama in partnership with Ponterra, Microsoft, and Carbon Streaming, a 250K+ acres restoration project in South Africa led by Imperative, and a collaboration with YvY Capital to scale up carbon investments in Brazil.
For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Lucas di Grassi:
Lucas di Grassi is a founding member of Formula E, has competed in every race up until now and is the most successful driver on the grid in terms of podium positions. He was winner of the first ever race in Beijing 2014, Champion in the 2016/2017 and teams' Champion in 2017/2018. In addition to his role as an ABT CUPRA driver, Lucas di Grassi is an entrepreneur for innovation, sustainability and electric mobility. As co-founder of Zero Summit he is organizing technology and business panels for a zero-carbon future in many countries around the world. Since 2018, Lucas di Grassi is an official United Nations Ambassador for Clean Air. Lucas di Grassi lives in Monaco together with his wife Bianca, his son Leonardo and his daughter Beatriz.
About Formula E:
As the world’s first all-electric FIA World Championship and the only sport certified net zero carbon since inception, the ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that partners with the world’s largest enterprises to help them achieve their sustainability goals while driving global decarbonization. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking decarbonization projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709047754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom